Universal chimeric natural killer receptor–modified T cells engineered to dual-target NKG2D and NKp44 (NCR2) ligands on tumors, triggering T-cell cytotoxicity and cytokine release.
T cells engineered with NK receptor–based chimeric receptors that dual-target ligands for NKG2D and NKp44 (NCR2) on tumor cells; ligand engagement triggers T‑cell activation signaling to drive cytotoxic killing and cytokine release, addressing antigen heterogeneity in solid tumors.
Engineered T cells express an NKG2D-based chimeric receptor that binds MICA on tumor cells, triggering CAR signaling and direct T-cell killing via perforin/granzyme release and apoptosis pathways, with cytokine release.
Universal chimeric natural killer receptor–modified T cells engineered to dual-target NKG2D and NKp44 (NCR2) ligands on tumors, triggering T-cell cytotoxicity and cytokine release.
T cells engineered with NK receptor–based chimeric receptors that dual-target ligands for NKG2D and NKp44 (NCR2) on tumor cells; ligand engagement triggers T‑cell activation signaling to drive cytotoxic killing and cytokine release, addressing antigen heterogeneity in solid tumors.
MICB is an NKG2D ligand; the NKG2D-based CAR on the engineered T cells binds MICB, activating the T cell to kill the target via perforin/granzyme-mediated cytotoxicity (with cytokine release), causing direct lysis.
Universal chimeric natural killer receptor–modified T cells engineered to dual-target NKG2D and NKp44 (NCR2) ligands on tumors, triggering T-cell cytotoxicity and cytokine release.
T cells engineered with NK receptor–based chimeric receptors that dual-target ligands for NKG2D and NKp44 (NCR2) on tumor cells; ligand engagement triggers T‑cell activation signaling to drive cytotoxic killing and cytokine release, addressing antigen heterogeneity in solid tumors.
CAR-engineered T cells bind ULBP1 (an NKG2D ligand) on tumor cells, triggering T-cell activation and direct killing via perforin/granzyme release (and death-receptor pathways) with cytokine release.
Universal chimeric natural killer receptor–modified T cells engineered to dual-target NKG2D and NKp44 (NCR2) ligands on tumors, triggering T-cell cytotoxicity and cytokine release.
T cells engineered with NK receptor–based chimeric receptors that dual-target ligands for NKG2D and NKp44 (NCR2) on tumor cells; ligand engagement triggers T‑cell activation signaling to drive cytotoxic killing and cytokine release, addressing antigen heterogeneity in solid tumors.
Engineered T cells bearing NKG2D-based chimeric receptors bind ULBP2 on tumor cells, triggering CAR-like activation and direct killing via perforin/granzyme release (and death receptor pathways).
Universal chimeric natural killer receptor–modified T cells engineered to dual-target NKG2D and NKp44 (NCR2) ligands on tumors, triggering T-cell cytotoxicity and cytokine release.
T cells engineered with NK receptor–based chimeric receptors that dual-target ligands for NKG2D and NKp44 (NCR2) on tumor cells; ligand engagement triggers T‑cell activation signaling to drive cytotoxic killing and cytokine release, addressing antigen heterogeneity in solid tumors.
ULBP3 is an NKG2D ligand; NK receptor–based CAR T cells bind ULBP3 on tumor cells, triggering CAR signaling and direct T‑cell cytolysis (perforin/granzyme and apoptosis) with cytokine release.